Compound: cinoxacin
SMILES: O=c1c(nn(CC)c2c1cc3OCOc3c2)C(=O)O
InChIKey: VDUWPHTZYNWKRN-UHFFFAOYSA-N
Synonyms: cinoxacin, 28657-80-9, Cinobac, Cinoxacino, Cinoxacine, Cinoxacinum, Lilly 64716, [1,3]Dioxolo[4,5-g]cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-, 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid, DTXSID8022822, 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid, LMK22VUH23, 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid, NSC-304467, CHEBI:3716, 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid, 1-ethyl-4-oxo-1H,4H,7H-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid, DTXCID202822, Clinoxacin, Azolinic Acid, (1,3)Dioxolo(4,5-g)cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-, Acid, Azolinic, cinoxacina, 1-ethyl-4-oxo-(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid, 1-ethyl-4-oxo-1H,4H,7H-(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid, 5-Ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta(b)naphthalene-7-carboxylic acid, 5-Ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid, RefChem:56762, J01MB06, 5-Ethyl-8-oxo-5,8-dihydro(1,3)dioxolo(4,5-g)cinnoline-7-carboxylic acid, 1-Ethyl-1,4-Dihydro-4-oxo (1,3) Dioxolo (4,5-g) Cinnoline-3-Carboxylic Acid, 249-133-8, Compound 64716, Cinobactin, Uronorm, 1-Ethyl-4-oxo-1,4-dihydro-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid, NSC 304467, MLS000069630, 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid, SMR000058232, NSC304467, NCGC00015277-02, Cinx, CAS-28657-80-9, (1,3)Dioxolo(4,5-g)cinnoline-3-carboxylic acid, 1,4-dihydro-1-ethyl-4-oxo-, Cinoxacine [INN-French], Cinoxacinum [INN-Latin], Cinoxacino [INN-Spanish], Noxigram, 1-ethyl-1,4-dihydro-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid, 1-ethyl-4-oxohydro-7H-1,3-dioxoleno[4,5-g]cinnoline-3-carboxylic acid, Cinobac (TN), SR-01000000129, EINECS 249-133-8, UNII-LMK22VUH23, BRN 1084304, CCRIS 8206, TNP00246, Prestwick_239, MFCD00056776, Cinoxacin [USAN:USP:INN:BAN:JAN], Spectrum_000152, CINOXACIN [INN], CINOXACIN [JAN], CINOXACIN [MI], CINOXACIN [USAN], Opera_ID_1392, Prestwick0_000780, Prestwick1_000780, Prestwick2_000780, Prestwick3_000780, Spectrum2_000570, Spectrum3_000352, Spectrum4_000289, Spectrum5_000749, CINOXACIN [VANDF], Lopac-C-8645, CINOXACIN [MART.], Epitope ID:768760, C 8645, cid_2762, CINOXACIN [WHO-DD], CHEMBL1208, Lopac0_000309, Oprea1_131085, SCHEMBL43770, BSPBio_000860, BSPBio_002043, KBioGR_000818, KBioSS_000632, MLS001148076, DivK1c_000318, SPECTRUM1500190, SPBio_000360, SPBio_002799, Cinoxacin (JP18/USP/INN), BPBio1_000946, orb1310769, orb3025774, CINOXACIN [ORANGE BOOK], CINOXACIN [USP IMPURITY], SCHEMBL29471771, BDBM39350, GTPL12401, HMS500P20, KBio1_000318, KBio2_000632, KBio2_003200, KBio2_005768, KBio3_001263, MSK5702, NINDS_000318, GLXC-07113, HMS1570K22, HMS1920O11, HMS2091E18, HMS2097K22, HMS2235K07, HMS3260N20, HMS3370B19, HMS3714K22, HMS5083E15, Pharmakon1600-01500190, MSK5702-100DM, HY-B1085, MSK5702-1000DM, Tox21_110121, Tox21_500309, CCG-39160, EBC-07472, MSK5702-100D, MSK5702-100M, NSC756695, SBB003082, AKOS022507372, MSK5702-1000D, Tox21_110121_1, CS-4652, DB00827, FC72005, LP00309, NSC-756695, SDCCGSBI-0050297.P005, Cinoxacin Solution in DMSO, 100ug/mL, IDI1_000318, NCGC00015277-01, NCGC00015277-03, NCGC00015277-04, NCGC00015277-05, NCGC00015277-06, NCGC00015277-07, NCGC00015277-08, NCGC00015277-09, NCGC00015277-10, NCGC00015277-11, NCGC00015277-12, NCGC00015277-13, NCGC00015277-14, NCGC00015277-17, NCGC00015277-21, NCGC00023754-03, NCGC00023754-04, NCGC00023754-05, NCGC00023754-06, NCGC00023754-07, NCGC00260994-01, AS-73151, Cinoxacin Solution in DMSO, 1000ug/mL, ST044511, Cinoxacin Solution in Methanol, 100ug/mL, SBI-0050297.P004, DB-047427, EU-0100309, NS00006827, SW196546-3, A12385, C08052, D00872, EN300-267813, AB00051948_17, AB00051948_18, Cinoxacin Solution in DMSO/Methanol, 100ug/mL, Cinoxacin Solution in DMSO/Methanol, 1000ug/mL, Q1639588, SR-01000000129-2, SR-01000000129-4, SR-01000000129-7, BRD-K14704277-001-05-1, BRD-K14704277-001-15-0, BRD-K14704277-001-22-6, BRD-K14704277-001-23-4, 1-Ethyl-1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid, Z2065671138, [1,5-g]cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-, 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylicacid, (1,3)DIOXOLO(4,5-G)CINNOLINE-3-CARBOXYLIC ACID, 1-ETHYL-1,4-DIHYDRO-4-OXO, 1-Ethyl-4-oxo-1,4-dihydro-7H-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
Theoretical properties:
molecular_formula: C12H10N2O5
molecular_weight: 262.22 g/mol
exact_mass: 262.05897142 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 2
heavy_atom_count: 19
topological_polar_surface_area: 88.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 261-262
solubility: 9.61e-01 g/L
Descriptions:
pubchem: Cinoxacin is a member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections. It has a role as an antiinfective agent and an antibacterial drug. It is an oxo carboxylic acid, an oxacycle and a member of cinnolines.
chebi: A member of the class of  cinnolines  that is 6,7-methylenedioxycinnolin-4(1<em>H</em>)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections.
chembl: CINOXACIN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Cinoxacin is a quinolone antibiotic that has been discontinued in the U.K. as well the United States, both as a branded drug or a generic. The marketing authorization of cinoxacin has been suspended throughout the EU.
Cinoxacin was an older synthetic antimicrobial related to the quinolone class of antibiotics with activity similar to oxolinic acid and nalidixic acid. It was commonly used thirty years ago to treat urinary tract infections in adults. There are reports that cinoxacin had also been used to treat initial and recurrent urinary tract infections and bacterial prostatitis in dogs. however this veterinary use was never approved by the United States Food and Drug Administration (FDA). In complicated UTI, the older gyrase-inhibitors such as cinoxacin are no longer indicated.